3/4
05:51 am
nrxp
NRx Pharmaceuticals (NRXP) was upgraded by Zacks Research from "strong sell" to "hold".
Low
Report
NRx Pharmaceuticals (NRXP) was upgraded by Zacks Research from "strong sell" to "hold".
3/3
11:46 am
nrxp
NRx Pharmaceuticals (NRXP) had its price target raised by HC Wainwright from $40.00 to $45.00. They now have a "buy" rating on the stock.
Low
Report
NRx Pharmaceuticals (NRXP) had its price target raised by HC Wainwright from $40.00 to $45.00. They now have a "buy" rating on the stock.
3/2
07:13 am
nrxp
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer [Yahoo! Finance]
Low
Report
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer [Yahoo! Finance]
3/2
07:00 am
nrxp
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
Low
Report
NRx Pharmaceuticals (Nasdaq: NRXP) Appoints Prof. Joshua Brown MD, PhD, as Chief Medical Innovation Officer
2/18
12:22 pm
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
2/17
08:03 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
2/17
07:13 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting [Yahoo! Finance]
Low
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting [Yahoo! Finance]
2/17
07:00 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
Low
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Path to New Drug Application with Real World Data and Broader Proposed Indication for NRX-100 (ketamine) Following Type C FDA Meeting
1/28
07:29 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/21
09:08 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright.
1/16
07:03 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 2025 Annual Meeting Date and Record Date
1/15
08:03 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
Low
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $25.00 price target on the stock.
1/14
07:03 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
Low
Report
NRx Pharmaceuticals (Nasdaq:NRXP) Announces 70,000 Patient Data on Real World Use of Ketamine for Treatment of Suicidal Depression to be Submitted to the FDA in Support of NRX-100 Approval
1/5
08:33 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $34.00 price target on the stock.
1/5
07:19 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions [Yahoo! Finance]
1/5
06:57 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) and neurocare Group AG Announce Joint Offering of Neuroplastic Therapy Targeting Depression, PTSD, and other mental health afflictions
1/2
07:03 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at Ascendiant Capital Markets.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at Ascendiant Capital Markets.
12/24
04:15 pm
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/18
04:39 pm
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/18
07:32 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion [Yahoo! Finance]
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion [Yahoo! Finance]
12/18
07:05 am
nrxp
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
Medium
Report
NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion
12/16
08:05 am
nrxp
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
High
Report
NRx Pharmaceuticals (NASDAQ:NRXP) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.